Respiratory Distress Syndrome – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23045IDB-L5

Select Item

Empower your strategies with our Respiratory Distress Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.

Respiratory distress syndrome (RDS) occurs in babies born early (premature) whose lungs are not fully developed. The earlier the infant is born, the more likely it is for them to have RDS and need extra oxygen and help breathing. It primarily affects premature infants due to insufficient surfactant, a lung-stabilizing substance. Without surfactant, the lungs collapse, causing breathing difficulties. Common in preterm births, symptoms include rapid breathing, grunting, nostril flaring, and cyanosis. Prompt diagnosis and treatment, often involving mechanical ventilation and surfactant replacement, are vital. While RDS is more prevalent in premature babies, it can also affect full-term infants with specific risk factors. Proactive neonatal care and surfactant therapy enhance lung function, significantly improving the prognosis for infants with RDS. Early detection and intervention are critical for optimal outcomes in managing respiratory distress in newborns.

The Respiratory Distress Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Distress Syndrome and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Respiratory Distress Syndrome
Key Targets
· Tyrosine Protein Kinase SYK; Interferon Alpha/Beta Receptor 1; Angiopoietin 1 Receptor; Interferon Alpha/Beta Receptor 2; Glucocorticoid Receptor; Membrane Primary Amine Oxidase; Interleukin 18 Receptor 1; MAP Kinase Activated Protein Kinase 2; Guanylate Cyclase; and Interleukin 18 Receptor Accessory Protein
Key Mechanisms of Action
· Tyrosine Protein Kinase SYK Inhibitor; Angiopoietin 1 Receptor Agonist; Glucocorticoid Receptor Agonist; Interferon Alpha/Beta Receptor 1 Agonist; Interferon Alpha/Beta Receptor 2 Agonist; IgG Receptor FcRn Large Subunit p51 Antagonist; Interleukin 18 Receptor 1 Antagonist; Interleukin 18 Receptor Accessory Protein Inhibitor; Membrane Primary Amine Oxidase Inhibitor; and Mitogen Activated Protein Kinase 14 Inhibitor
Key Routes of Administration
· Intravenous; Inhalational; Oral; Parenteral; Subcutaneous; Topical; Nasal; Intraarticular; Intravenous Drip; and Intravenous Bolus
Key Molecule Types
· Small Molecule; Cell Therapy; Monoclonal Antibody; Synthetic Peptide; Recombinant Protein; Biologic; Gene Therapy; Gene-Modified Cell Therapy; Peptide; and Recombinant Enzyme
Major Companies
· Chiesi Farmaceutici SpA; BioStem Technologies Inc; Pantherna Therapeutics GmbH; Omnispirant Ltd; Suzhou Regend Therapeutics Co Ltd; Therapeutic Solutions International Inc; Aqualung Therapeutics Corp; Center for Genetic Engineering and Biotechnology; Cellvation Inc; and Meridigen Biotech Co Ltd

Scope

  • Therapeutics in Development: Covering 131 molecules, with 126 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Respiratory Distress Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Respiratory Distress Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Respiratory Distress Syndrome treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

A6 Pharmaceuticals LLC
AATec Medical GmbH
Abbreos Inc
AcelRx Pharmaceuticals Inc
Akttyva Therapeutics Inc
Alveolus Bio Inc
AMNICELL Corp Ltd
Aodh Lifesciences Pvt Ltd
APEIRON Biologics AG
Aqualung Therapeutics Corp
ARBORMED Pharmaceuticals Inc
Arch Biopartners Inc
Asia Cell Therapeutics (Shanghai) Co Ltd
AVM Biotechnology LLC
AzarGen Biotechnologies (Pty) Ltd
Beijing Northland Biotech Co Ltd
BerGenBio ASA
Bill & Melinda Gates Medical Research Institute
BioAegis Therapeutics Inc
BioMarck Pharmaceuticals Ltd
BioRestorative Therapies Inc
BioStem Technologies Inc
BioSuperior Technology Inc
Biotech Pharmaceutical Co Ltd
Biotest AG
Bioxytran Inc
Biozeus Pharmaceutical SA
Bonus BioGroup Ltd
Cartesian Therapeutics Inc
Cellular Biomedicine Group Ltd
Cellvation Inc
Center for Genetic Engineering and Biotechnology
Chiesi Farmaceutici SpA
Children's Hospital Pennsylvania
Chrysalis BioTherapeutics Inc
Claritas Pharmaceuticals Inc
CMTx Biotech Inc
Cytonus Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Dale Biotech LLC
Degranin Therapeutics LLC
Direct Biologics LLC
Dompe Farmaceutici SpA
Endece LLC
Eunoia Biotech LLC
Exorphia Co Ltd
Exvastat Ltd
Faron Pharmaceuticals Oy
Gamaleya Federal Research Center of Epidemiology and Microbiology
GC Biopharma Corp
GEn1E Lifesciences Inc
GentiBio Inc
Grand Pharmaceutical Group Ltd
Guangzhou Saijun Biological Technology Co Ltd
Haisco Pharmaceutical Group Co Ltd
Hansa Biopharma AB
Histocell SL
IcanoMAB GmbH
ImmunityBio Inc
Imstem Biotechnology Inc
In2cure AB
InnoMab Pte Ltd
Jiangyin Usun Pharmaceutical Co Ltd
Kalvista Pharmaceuticals Inc
Keli Therapeutics
Kubota Vision Inc
Lee's Pharmaceutical Holdings Ltd
LTT Bio-Pharma Co Ltd
Mallinckrodt Plc
MannKind Corp
MDI Therapeutics Inc
Medical University of South Carolina
MediciNova Inc
MediPost Co Ltd
Medsenic SAS
Meridigen Biotech Co Ltd
MetrioPharm AG
Molecular Express Inc
Nano Biotherapeutics Inc
Nano24med
Neutrolis Inc
Northern Therapeutics Inc
NS Pharma Inc
Nuvara Therapeutics LLC
OGB1 Inc
Omnispirant Ltd
Paean Biotechnology Inc
Panag Pharma Inc
Pantherna Therapeutics GmbH
PharmAbcine Inc
PharmaIN Corp
Relief Therapeutics Holding AG
Restore Therapeutics LLC
Revolo Biotherapeutics Ltd
Rise Therapeutics LLC
Riserx LLC
RS BioTherapeutics Inc
S-Evans Biosciences Inc
Shanghai Henlius Biotech Inc
Signablok Inc
SolAeroMed Inc
Sorrento Therapeutics Inc
Spirrow Therapeutics
Staidson BioPharma Inc
Suzhou Regend Therapeutics Co Ltd
Systimmune Inc
The Lundquist Institute
Theratome Bio Inc
Thetis Pharmaceuticals LLC
Tianjin Angsai Cell Genetic Engineering Co Ltd
Trove Therapeutics Inc
Vasomune Therapeutics Inc
VGSK Technologies Inc
Vironova Medical AB
Xfibra Inc
Xintela AB
Zephyrm Biotechnologies Co Ltd
Zhejiang Quansheng Biotechnology Co Ltd
Zydus Lifesciences Ltd
ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Respiratory Distress Syndrome reports
Pharmaceuticals
New
Pharma M&A Deals H1 2026 - Top Themes: Strategic Intelligence
$495 | July 2026
Pharmaceuticals
New
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment,…
$17,995 | July 2026
Pharmaceuticals
New
Melanoma: Epidemiology Forecast to 2035
$9,995 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Respiratory Distress Syndrome – Drugs In Development, 2024 in real time.

  • Access a live Respiratory Distress Syndrome – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more